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Abstract 
Giant gastrointestinal stromal tumors (GISTs) of the rectum are rare and often difficult to 
remove surgically. At the time metastases are found, GISTs are considered to be 
incurable and until recently no adequate therapy was of any value for these patients. 
Recently, imatinib was introduced: a signal transducing inhibitor acting specifically on 
the KIT-tyrosine kinase, which can be used to downsize giant GIST (neo-adjuvant) before 
surgery or induce stable disease in case of metastases with few minor side-effects. Two 
patients with giant rectal GIST are presented, one of which was treated before the 
imatinib era, the other when imatinib was available. 
 
Introduction 
Gastrointestinal stromal tumors (GISTs) are rare tumors, but still are the most 
common mesenchymal tumors of the gastrointestinal tract (approximately 80%). Mostly 
they occur in the stomach (60–70%) and in the small bowel (20–30%). Localisation in the 
esophagus is rare (<5%) and they are found in the colon and rectum in approximately 5–
10% of cases [1–3]. 
GISTs can become very large, and when their size reaches over 10 cm, they are referred 
to as ‘giant GIST’. These giant types may occur everywhere in the gastrointestinal tract 
but will grow to these sizes especially in those regions where they may cause the least 
symptoms at a certain size. Rectal obstruction is a late symptom, as duodenal obstruction 
might become symptomatic already with a smaller diameter of the tumor. Therefore, 
clinical presentation mainly depends on tumor size and localisation or is determined by 
metastatic disease or in-growth in adjacent organs.  
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The most frequent complaint of patients with a rectal GIST is change in bowel 
movement due to tumor size and/or gastrointestinal bleeding, when the overlying mucosa 
is ulcerated. Other symptoms are abdominal discomfort and urinary disorders by 
compression of the bladder. 
Surgical removal remains the only curative treatment for patients with GIST [5], but 
tumors with metastasis are considered to be inoperable. Chemotherapy and/or 
radiotherapy showed to have disappointing results [1, 6] and no remarkable response may 
be expected from neither of these two. 
Recently, a new drug, imatinib (STI-571), was launched, and many promising results 
already have been reported. Imatinib is a signal transduction inhibitor, inhibiting 
amongst others the signalling of the KIT-tyrosine kinase, which switches the balance 
towards reduced cellular proliferation and increased apoptosis [4]. Good results have 
been reported in the treatment of locally irresectable or metastatic GIST, in terms of 
partial response or stable disease [4, 7, 8]. The effect of imatinib as (neo-)adjuvant is 
further being investigated. Bümming et al. have reported some promising results [7], but 
the effect of imatinib as adjuvant and neo-adjuvant needs further investigation in 
prospective randomised clinical trials. 
This case report is the first report of two patients treated for a giant rectal GIST, one 
patient with a giant GIST treated before the introduction of imatinib, the other one 
treated after the availability of imatinib. 
Cases 
Case 1 
A 65-year-old woman, a Jehova’s Witness, attended our hospital with vague abdominal pain, urge 
and occasional rectal bleeding. There was no change in bowel movement and her weight was stable. Her 
medical history reported hypertension and a hiatal hernia. Physical examination showed an obese (105 
kg, 173 cm) vital woman. Rectal examination showed a large palpable mass located posteriorly close to 
the pelvic floor. At sigmoidoscopy, a giant ulcerating tumor was seen from 2 to 18 cm in the posterior 
wall of the rectum. The central ulceration was probably caused by tumor compression of the rectum. 
Abdominal CT and MRI demonstrated a large tumor of at least 10 cm cross-section on the dorsal side of 
the rectal wall without invasion or ingrowth in adjacent organs, but with intralesional bleeding (fig. 1). 
Ultrasonography of the liver and chest X-ray showed no lesions suspect for metastases. 
At this point the diagnosis was a mesenchymal tumor. Since she was bleeding persistently, and 
radiotherapy and chemotherapy did not seem a valid option for this kind of tumor, the patient went for 
surgery. After hemodilution and using the cell saver, an abdominoperineal resection of the rectum with 
colostoma was performed. A sacral plexus bleeding complicated surgery. Since it was not permitted to 
administer blood products, the pelvis was packed at a hemoglobin level of 2 mmol/l. The gauze were left 
in for a week, and removed when the hemoglobin level was 3 mmol/l. Her further recovery was 
uneventfull. 
Pathological examination of the resected specimen showed a GIST of the rectal wall with diffuse C-
kit positivity. The high mitotic rate (18 mitotic figures per 2 mm
2) and the large tumor size (15 cm) 
indicate high malignant potential. The capsule was ruptured so that complete removal of the tumor 
could not be ensured. 
Approximately one year after resection of the primary tumor, a hypodense lesion was found in the 
liver with routine ultrasound. The subsequent CT scan showed recurrent disease in the iliac fossa and in 
the liver. At that time imatinib was available and administered in a daily dose of 400 mg. As a sign of 
response the metastases typically became clearer at CT follow-up. Until now, almost three years after 
initiation of imatinib therapy, she has stable disease.  
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Case 2 
A 62-year-old man was referred to the surgeon and urologist because of progressive obstipation, 
painful defecation and voiding problems. In the past 6 months he lost 17 kg in weight. Physical 
examination showed a jaundiced man. The liver was not palpable. Rectal examination revealed a 
palpable tumor, 5 cm proximal to the dentate line. 
Blood tests showed elevated liver enzymes and bilirubin. Endosonography of the rectum 
demonstrated a submucosal tumor. A CT scan of the abdomen showed a large extraluminal tumor in 
the rectum compressing the lumen and multiple hypodense lesions in the liver, suspect for being 
metastases. One of these lesions counted 8.9 × 8.6 cm and one was compressing the bile system. 
Furthermore, there was a solitary lung lesion suspected for lung metastasis. 
Ultrasound-guided needle biopsy of the liver lesions showed a tumor composed of polymorphic 
spindle cells with a positive C-kit immunohistochemical staining, infiltrating pre-existent liver 
parenchyma (fig. 2). Furthermore these lesions showed necrosis and a high mitotic rate, consistent with 
a metastasis of a malignant GIST. 
Imatinib at a dose of 400 mg once daily was initiated. Within a couple of weeks his symptoms of 
obstruction, voiding problems and disturbed liver function decreased. Follow-up CT scan showed 
regression and clarification of the GIST and metastases as a sign of response (fig. 3). 
Discussion 
Until recently, the prognosis of patients with a giant GIST of the rectum was very poor, 
especially when metastases were present at time of diagnosis. Radiotherapy and 
chemotherapy are not effective in treating these tumors or metastasis and surgery used to 
be the only therapeutical option for non-metastatic disease [1]. The development of the 
new drug imatinib (Glivec
TM) improved the therapeutic options tremendously. Where 
giant GIST used to be irresectable and metastatic disease uncontrollable, imatinib offers 
the opportunity of tumor regression and stable disease. In the EORTC study for GISTs, 
complete response was 7%, partial response 25%, stable disease was reached in 24% of the 
cases, and in 14% there was no effect and disease progressed after starting imatinib 
treatment. 
Long-term follow-up must be awaited to clarify the behavior of the tumor and 
metastases on long-term treatment with this new tyrosine kinase inhibitor. Verweij et al. 
found that to achieve response induction, a daily dose of 400 mg is sufficient to reach this 
goal, but a dose of 400 mg twice a day achieves significantly longer progression-free 
survival, especially in widespread metastatic disease [9]. 
Imatinib as a neo-adjuvant to downsize giant GIST of the rectum before surgery might 
help reach resectability of the tumor. At the time the first patient, case 1, attended our 
hospital, the drug was not available for clinical use in The Netherlands. At present, first a 
treatment with imatinib would be initiated to downsize the tumor in order to improve the 
likelihood of a radical resection and reduce perioperative morbidity. Surgery remains the 
only chance of complete removal of the GIST. As an adjuvant, imatinib is promising in 
reaching stable disease and prolong symptom-free interval after surgery, especially in 
metastatic disease or when local recurrence occurs [10]. 
At the time of diagnosis approximately 10–50% of patients have overtly metastatic 
disease [4]. For large irresectable symptomatic gastrointestinal tumors of the rectum with 
metastatic spread, single therapy with this drug might also be an option to decrease 
symptoms and even no surgery will be necessary in some cases. This is shown in case 2, 
where stable disease was reached and symptoms disappeared after starting imatinib. For  
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now, long-term follow-up and prospective trials are needed to explore the possibilities of 
this novel drug which is a breakthrough in the treatment of a potentially lethal disease. 
 
 
 
 
 
Fig. 1. MRI scan showing a large mass in the lower abdomen and pelvis, with intralesional bleeding. 
 
 
 
Fig. 2. Gastrointestinal stromal tumor (GIST). a A polymorphic spindle cell tumor infiltrating pre-
existent liver parenchyma (right side). Hematoxylin and eosin; original magnification ×200. b The 
tumor shows diffuse c-kit positivity. C-kit; original magnification ×100. 
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Fig. 3. CT scan showing both regression of tumor (a) and metastasis (c) after 3 months of Glivec 
therapy (b, d). 
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